Drug in Combination Aids Depressive Symptoms


Using aripiprazole, commonly known as Abilify, in combination with older patients’ existing anti-depression treatment reduced depressive symptoms

Using aripiprazole, commonly known as Abilify, in combination with older patients’ existing anti-depression treatment reduced depressive symptoms, according to findings published in The Lancet.

Researchers from Washington University School of Medicine in St. Louis studied 468 patients aged 60-years or older with treatment resistant depression in order to assess the safety and efficacy of aripiprazole, and to test its association with a higher probability or remission. The participants were recruited from 3 centers in the United States and Canada and were assigned to receive the addition of aripiprazole 10 mg daily or placebo for 12 weeks.

In prior studies, the researchers explained, younger patients who added aripiprazole to their treatment plans demonstrated decreased symptoms when the antidepressant alone was not effective.

In the current study, researchers demonstrated that the same was true for older patients: those who added aripiprazole saw their depressive symptoms reduced.

“This is a rare study because it looks at depression specifically in older adults,” study co-author Dr. Benoit Mulsant, MD, explained in a press release. “It’s important to treat older adults effectively, especially given that adults with late life depression are at an increased risk of developing dementia. Our research demonstrates that older adults respond to treatment for depression.”

In the second phase of the study — in which patients who did not respond to venlafaxine continued to receive the drug in combination with either aripiprazole or a placebo – using two drugs led to a remission of depression in 44% of the patients in the study, compared to less than a third (29%) of the patients in the placebo group.

“We know that in older adults with depression, about half will not respond to medication,” first author and principal investigator Eric J. Lenze, MD, continued. “They may have a minimal response, but they’ll still be depressed. The question we wanted to answer was whether there was anything else we could do for them.”

The study authors added that weight gain and metabolic problems, traditional side effects that they expected to see, were not present in this study.

“Antipsychotic medications can cause increasing amounts of fat and thereby increase blood sugar, potentially contributing to diabetes,” Lenze said. “But compared with placebo, aripiprazole was no more likely to produce increased fat in these patients and had no effect on blood sugar, insulin or lipids.”

Related Videos
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Katharine Phillips, MD: Various Treatments for Obsessive-Compulsive Disorders
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
© 2024 MJH Life Sciences

All rights reserved.